Molecular Diagnostics for sepsis
SIRS-Lab in Sepsis
Working within an active scientific community, SIRS-Lab is a major player in national and European-wide sepsis networks.
Company advisors are key opinion leaders in the field of inflammatory disorders and syndromes. Staff includes experienced managers, physicians, pharmacists, and research scientists coming from multiple countries.
The company applies the latest molecular diagnostic techniques while leveraging the expert knowledge of its staff and advisors in areas such as critical care medicine, microbiology, assay design, and gene expression.
SIRS-Lab is actively involved with the German Sepsis Society e.V., the European Society of Intensive Care Medicine, the Competence Network SepNet, the Public Health Research Institute, Newark, USA, the Hans-Knöll-Institute, Jena and the universities of Paris, London, Nancy, Prague, Brno, Berlin, Erlangen, Frankfurt/M., Jena, Marburg, Munich, Tübingen and Ulm.
History
SIRS-Lab was founded in 2000, emerging from the University Hospital in Jena. Business operations began in 2001 and by the end of 2003 SIRS-Lab had made its 50th patent application. The year 2005 saw the launch of the first commercially available product (LOOXSTER), a sample preparation system that concentrates the DNA of pathogens (bacteria and fungi) from complex samples such as whole blood.
LOOXSTER is now a key component of VYOO, the company's diagnostic test for rapid pathogen detection, launched in 2007.
In parallel with product development, SIRS-Lab has utilized a unique biobank to identify and evaluate proprietary sepsis biomarkers to enable monitoring of patient's immune response during early sepsis and subsequent treatment.
In 2008, SIRS-Lab received CE approval for VYOO and IVD (in vitro diagnostics) Quality Management certification EN ISO 13485.
Finance
SIRS-Lab is a privately held company. Lead investors are Affentranger Associates SA, Geneva, Switzerland and bm-t beteiligungsmanagement thüringen gmbh, Erfurt, Germany.
Intellectual Property
SIRS-Lab has an extensive intellectual property portfolio demonstrating the innovativeness of its staff and providing an excellent basis for the development of a sustainable product pipeline. To date, the company has made more than 90 patent applications.
